Susquehanna International Group
VERV

Susquehanna International Group’s Verve Therapeutics VERV Stock Holding History

Susquehanna International Group’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-82,000
Closed -$921K – 13993
2025
Q2 		$921K Buy
82,000
+36,900
+82% +$210K ﹤0.01% 7648
2025
Q1 		$206K Buy
45,100
+12,000
+36% +$80.4K ﹤0.01% 10874
2024
Q4 		$187K Buy
33,100
+4,200
+15% +$23.7K ﹤0.01% 10804
2024
Q3 		$140K Sell
28,900
-52,600
-65% -$306K ﹤0.01% 10805
2024
Q2 		$398K Sell
81,500
-57,600
-41% -$362K ﹤0.01% 8807
2024
Q1 		$1.85M Sell
139,100
-5,500
-4% -$72.9K ﹤0.01% 5525
2023
Q4 		$2.02M Buy
144,600
+95,800
+196% +$1.19M ﹤0.01% 5334
2023
Q3 		$647K Buy
48,800
+26,600
+120% +$428K ﹤0.01% 7630
2023
Q2 		$416K Buy
+22,200
New +$370K ﹤0.01% 8743
2023
Q1 		– Sell
-47,600
Closed -$921K – 13556
2022
Q4 		$921K Buy
47,600
+12,600
+36% +$334K ﹤0.01% 6374
2022
Q3 		$1.2M Buy
+35,000
New +$1.12M ﹤0.01% 6160
2022
Q2 		– Sell
-15,800
Closed -$361K – 14022
2022
Q1 		$361K Buy
15,800
+5,300
+50% +$151K ﹤0.01% 9808
2021
Q4 		$387K Buy
+10,500
New +$441K ﹤0.01% 9871

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Susquehanna International Group's VERV Position: Q3 2025 in Review

Susquehanna International Group sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 82,365 shares — an estimated $925K sold.

Susquehanna International Group first reported a position in VERV in Q2 2021 and held it in 16 quarters. The position peaked at $3.35M in Q3 2022. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Susquehanna International Group reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Susquehanna International Group sold 82,365 Verve Therapeutics shares in Q3 2025, an estimated $925K.
  • Susquehanna International Group first reported a position in Verve Therapeutics in Q2 2021 and held it in 16 quarters.
  • Susquehanna International Group's Verve Therapeutics position peaked at $3.35M in Q3 2022.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.